Neurofibroma
A moderately firm, benign, encapsulated tumor resulting from proliferation of SCHWANN CELLS and FIBROBLASTS that includes portions of nerve fibers. The tumors usually develop along peripheral or cranial nerves and are a central feature of NEUROFIBROMATOSIS 1, where they may occur intracranially or involve spinal roots. Pathologic features include fusiform enlargement of the involved nerve. Microscopic examination reveals a disorganized and loose cellular pattern with elongated nuclei intermixed with fibrous strands. (From Adams et al., Principles of Neurology, 6th ed, p1016)
Subtype terms (3)
More specific conditions that are subtypes of Neurofibroma in the MeSH hierarchy.
- Neurofibroma, Plexiform
18 drugs (13 approved, 5 experimental)
- Neurofibromatoses
21 drugs (17 approved, 4 experimental)
- Neurofibrosarcoma
38 drugs (27 approved, 11 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (1)
Phase 2 trials (15)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (62)
- Takeda
- AstraZeneca
- Genentech
- Pfizer
- Novartis
- Array BioPharma
- Bayer
- Betta Pharmaceuticals Co.,Ltd.
- GlaxoSmithKline
- PTC Therapeutics
- Simcere Pharmaceutical Co., Ltd
- Fundação Educacional Serra dos Órgãos
- National Institutes of Health (NIH)
- United States Army
- Region Skane
- Beijing Tiantan Hospital
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Burzynski Research Institute
- University of London
- Cornell University
- Harvard University
- Indiana University
- Johns Hopkins University
- Lund University
- McGill University
- Michigan State University
- New York University
- Northwestern University
- +32 more
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (1)